Strategic Diagnostics (SDIX), a biotechnology-based products provider, reported fourth-quarter net income of $1.7 million or $0.08 per share, compared to a net loss of $260,000 or $0.01 per share last year.
Results for the quarter included income from discontinued operations of $3.2 million
Revenues for the quarter declined to $5.5 million from $6.3 million last year.
by RTT Staff Writer
For comments and feedback: email@example.com